Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

MedStar author(s):
Citation: Future Science OA. 4(1):FSO249, 2018 JanPMID: 29255621Institution: MedStar Washington Hospital CenterDepartment: Medicine/Endocrinology | Pathology | Surgery/Endocrine Surgery | Surgery/General SurgeryForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2018ISSN:
  • 2056-5623
Name of journal: Future science OAAbstract: Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.All authors: Boyle L, Burman KD, Carrol N, Felger E, Jonklaas J, Klubo-Gwiezdzinska J, Krishnan J, Liu D, Loh YP, Murthy SFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-01-18
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29255621 Available 29255621

Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.

Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.

Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.

Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.

English

Powered by Koha